Nanomaterials with dual immunomodulatory functions for synergistic therapy of breast cancer brain metastases

• DOI: 10.1016/j.bioactmat.2023.04.021
• Publication Date: 2023-04-27T03:03:11Z
• Authors: Zhenhao Zhao; Chufeng Li; Yiwen Zhang; Chao Li; Yongchao Chu; Xuwen Li; Peixin Liu; Hongyi Chen; Yu Wang; Boyu Su; Qinjun Chen; Tao Sun; Chen Jiang
• Keywords: STAT3; QH301-705.5; Drug delivery; TA401-492; Microenvironmental regulation; Biology (General); Materials of engineering and construction. Mechanics of materials; Immunogenic cell death; Article; 3. Good health; Breast cancer brain metastases

A long-standing paucity of effective therapies results in the poor outcomes of triple-negative breast cancer brain metastases. Immunotherapy has made progress in the treatment of tumors, but limited by the non-immunogenicity of tumors and strong immunosuppressive environment, patients with TNBC brain metastases have not yet benefited from immunotherapy. Dual immunoregulatory strategies with enhanced immune activation and reversal of the immunosuppressive microenvironment provide new therapeutic options for patients. Here, we propose a cocktail-like therapeutic strategy of microenvironment regulation-chemotherapy-immune synergistic sensitization and construct reduction-sensitive immune microenvironment regulation nanomaterials (SIL@T). SIL@T modified with targeting peptide penetrates the BBB and is subsequently internalized into metastatic breast cancer cells, releasing silybin and oxaliplatin responsively in the cells. SIL@T preferentially accumulates at the metastatic site and can significantly prolong the survival period of model animals. Mechanistic studies have shown that SIL@T can effectively induce immunogenic cell death of metastatic cells, activate immune responses and increase infiltration of CD8+ T cells. Meanwhile, the activation of STAT3 in the metastatic foci is attenuated and the immunosuppressive microenvironment is reversed. This study demonstrates that SIL@T with dual immunomodulatory functions provides a promising immune synergistic therapy strategy for breast cancer brain metastases.